Kardos, Peter http://orcid.org/0000-0002-4725-4820
Vogelmeier, Claus F.
Worth, Heinrich
Buhl, Roland
Obermoser, Victoria
Criée, Carl-Peter
Funding for this research was provided by:
Novartis Pharma
Article History
Received: 2 January 2020
Accepted: 24 April 2020
First Online: 4 May 2020
Compliance with Ethical Standards
:
: Dr Kardos reports personal fees from Novartis, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Menarini and Takeda, all of which are outside the submitted work. Dr Vogelmeier reports personal fees from Almirall, Cipla, Berlin Chemie/Menarini, CSL Behring and Teva, grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Mundipharma, Novartis and Takeda, and grants from the German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), Bayer Schering Pharma AG, MSD and Pfizer, all of which are outside the submitted work. Dr Worth reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Klosterfrau, Menarini, Novartis, Omron and Takeda, all of which are outside the submitted work. Dr Buhl reports personal fees from AstraZeneca, Chiesi, Cipla, Sanofi, and Teva, and grants and personal fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis and Roche, all of which are outside the submitted work. Dr Obermoser is employed by Novartis, the sponsor of the study. Dr Criée reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Klosterfrau, Menarini, Novartis, Omron, Sanofi and Takeda, all of which are outside the submitted work.
: All patients provided written informed consent prior to inclusion. The study was approved by the ethics committee of the University of Erlangen-Nuremberg.